In a survey of pediatric patients with vitiligo, only 51.4% were offered narrowband ultraviolet B (NB-UVB) phototherapy, and 45.1% received this treatment before the age of 18 years. The main barriers ...

In a phase 2 study, adding narrow-band UVB phototherapy (NB-UVB) resulted in meaningful repigmentation through week 48 without new safety concerns in patients with nonsegmental vitiligo who did not ...

New Orleans, LA – A randomized, placebo-controlled pilot study led by Frank Lau, MD, FACS, Associate Professor of Clinical Surgery at LSU Health New Orleans School of Medicine, has found that ...

A 12-month real-world cohort (n=500) showed statistically significant VASI reductions across all treatments, with NB-UVB and JAK inhibitor monotherapies outperforming TCS/TCI alone. Combination ...

Please provide your email address to receive an email when new articles are posted on . At week 24, the ritlecitinib plus nbUVB group saw a higher facial vitiligo severity change from baseline vs. the ...

Credit: Getty Images The Vitiligo Task Force developed expert-based recommendations for the treatment of vitiligo, worldwide. The International Vitiligo Task Force has issued up-to-date evidence-based ...

A retrospective study investigated skin cancer risk in a large cohort of patients treated with ultraviolet light therapy between May 1977 and November 2018. Patients were treated with narrowband UVB ...

SCENESSE® is being evaluated as a systemic repigmentation therapy for vitiligo patients, with a clinical focus on adolescent (12 years and above) and adult patients with darker skin types (Fitzpatrick ...

EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” ...

A retrospective cohort study found no significant associations between phototherapy without psoralens and the risk of skin cancer. Patients undergoing phototherapy without psoralens are not at an ...